| Literature DB >> 33864001 |
Nawab Azizi1,2, Jelena Toma1,2,3, Mickenzie Martin1,2,4, Muhammad Faran Khalid1,5, Fatemeh Mousavi1,2, Phyo Wei Win1,5, Maria Teresa Borrello6, Nina Steele7, Jiaqi Shi7, Marina Pasca di Magliano8, Christopher L Pin9,10,11,12.
Abstract
The unfolded protein response (UPR) is activated in pancreatic pathologies and suggested as a target for therapeutic intervention. In this study, we examined activating transcription factor 3 (ATF3), a mediator of the UPR that promotes acinar-to-ductal metaplasia (ADM) in response to pancreatic injury. Since ADM is an initial step in the progression to pancreatic ductal adenocarcinoma (PDAC), we hypothesized that ATF3 is required for initiation and progression of PDAC. We generated mice carrying a germline mutation of Atf3 (Atf3-/-) combined with acinar-specific induction of oncogenic KRAS (Ptf1acreERT/+KrasG12D/+). Atf3-/- mice with (termed APK) and without KRASG12D were exposed to cerulein-induced pancreatitis. In response to recurrent pancreatitis, Atf3-/- mice showed decreased ADM and enhanced regeneration based on morphological and biochemical analysis. Similarly, an absence of ATF3 reduced spontaneous pancreatic intraepithelial neoplasia (PanIN) formation and PDAC in Ptf1acreERT/+KrasG12D/+ mice. In response to injury, KRASG12D bypassed the requirement for ATF3 with a dramatic loss in acinar tissue and PanIN formation observed regardless of ATF3 status. Compared to Ptf1acreERT/+KrasG12D/+ mice, APK mice exhibited a significant decrease in pancreatic and total body weight, did not progress through to PDAC, and showed altered pancreatic fibrosis and immune cell infiltration. These findings suggest a complex, multifaceted role for ATF3 in pancreatic cancer pathology.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33864001 PMCID: PMC8173475 DOI: 10.1038/s41388-021-01771-z
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867